Miltenyi Biotec, Gmbh

Miltenyi Biotec B.v. Co., Kg

Xentech

Olaf Hardt

Andreas Bosio

Dominik Eckardt

Andrzej Dzionek

Jutta Kollet

Stefan Tomiuk

Kristin Becker

Stefano Cairo

David Joel Agorku

David Agorku

Andrea Aloia

Evgeniya Petrova

Jean-Gabriel Judde

Olivier Deas

Andeas Bosio

The present invention provides a cell culture for obtaining an epithelial organoid, the cell culture comprising i) epithelial stem cells, or tissue fragments comprising said epithelial stem cells, ii) a basal medium for animal or human cells, iii) a Bone Morphogenetic Protein (BMP) inhibitor, iv) a mitogenic growth factor selected from the group consisting of epidermal growth factor (EGF), transforming growth factor-alpha (TGF-alpha), basic fibroblast growth factor (bFGF), brain-derived neurotrophic factor (BDNF) and keratinocyte growth factor (KGF), v) at least one soluble culture enhancer, wherein said at least one culture enhancer induces correct polarization of the cells in said cell culture within the developing organoid such as a laminin/entactin complex or entactin, and vi) a Wnt agonist if said epithelial stem cells, or tissue fragments comprising said epithelial stem cells are healthy cells, wherein said at least one soluble culture enhancer in said cell culture is a laminin/entactin complex in a concentration between 0.2 mg/ml and 3.4 mg/ml. A cell culture medium, an in-vitro method for obtaining an epithelial organoid, and an epithelial organoid obtained by said method are also disclosed.

Cell culture medium and method for generation of epithelial organoids from epithelial stem cells

The present invention is directed to ligand like a chimeric antigen receptor (CAR), comprising an antigen binding domain specific for one or more antigens selected from the group consisting of CLA, CD142, CD73, CD49c, CD66c, CD104, CD318 and TSPAN8; cell populations expressing such CARs and the use of the cell populations for cancer therapy.

Chimeric antigen receptor specific for tumor cells

The present invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain specific for SSEA4, a population of engineered cells expressing said CARs, and a pharmaceutical composition comprising said genetically modified cells expressing said CARs. The pharmaceutical composition may be for use of the treatment of cancer in a subject suffering from cancer, wherein at least a subpopulation of the cancerous cells of said cancer expresses SSEA4.

Chimeric antigen receptor specific for SSEA4 antigen

A process for depleting host cells from a xenograft of human cells on a murine host is disclosed. The process includes fragmenting the xenograft, subjecting the sample to antibodies specific for a murine CD9 epitope coupled to a detection means, depleting the cell suspension from cells bound by the CD9-antibodies using the detection means, and collecting the cells not bound by the CD9-antibodies as target cells.

Depletion of mouse cells for isolation of human cells

Growing community of inventors

Cologne, Germany

Olaf Hardt